Home › Compare › GETVV vs ABBV
GETVV yields 90.09% · ABBV yields 3.06%● Live data
📍 GETVV pulled ahead of the other in Year 1
Combined, GETVV + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GETVV + ABBV for your $10,000?
Getnet Adquirência e Serviços Para Meios de Pagamento S.A. operates in the acquiring and services market for means of payment regulated by the Council National Monetary Council and the Central Bank of Brazil. The company engages in the provision of accreditation services for commercial and service establishments for accepting credit and debit cards; capturing, transmission, and processing of data and information; management of payments and receipts made to establishments accredited to its network; and installation, uninstallation, monitoring, supply, maintenance, and leasing of equipment used in transaction capture networks. It also engages in the development and marketing or licensing of software; commercializing products or distributing services of companies that provide cadastral information; provision of technical, commercial, and logistic infrastructure services for the business related to the receipt of accounts from concessionaires, banks, and other collection documents; and issuing electronic money. The company was formerly known as Farthi Empreendimentos e Participações S.A. and changed its name to Getnet Adquirência e Serviços para Meios de Pagamento S.A. in August 2014. The company was founded in 2008 and is based in São Paulo, Brazil. Getnet Adquirência e Serviços para Meios de Pagamento S.A. operates as a subsidiary of Banco Santander (Brasil) S.A.
Full GETVV Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.